TreatmentsMar 22, 2023
New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
SMA Newsroom
Clinical trialsMar 13, 2023
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).
OdySMA goes live!
Today we want to celebrate with you the official launch of our OdySMA project. OdySMA is an initiative that aims at one and only goal: that no one is left behind in the access to treatment journey.
OdySMA is a dynamic tool that we are using to create an SMA atlas that visualises systematically collected data to illustrate access pathways. The goal is to reveal the 'quest to access' of people living with SMA by mapping, visualising and centralising knowledge and data around access issues.
OtherJan 20, 2023
Nicole Gusset becomes the new CEO of SMA Europe
From SMA Europe we are excited to announce the appointment of Nicole Gusset as our new CEO.
Nicole Gusset has extensive experience working alongside SMA Community. Nicole’s first-born daughter Victoria was diagnosed with SMA Type II in 2011. As a result of this, in 2012, Nicole founded the patient organisation SMA Schweiz. She has been appointed as the President of SMA Europe since 2021 and now, will be holding the position of CEO in SMA Europe.